Article
Clinical Neurology
Jeffrey A. Cohen, Michelle H. Cameron, Myla D. Goldman, Andrew D. Goodman, Aaron E. Miller, Anne Rollins, Lily Llorens, Rajiv Patni, Robert Elfont, Reed Johnson
Summary: The study demonstrates that 274mg ADS-5102 is more effective in improving walking speed compared to placebo, meeting its primary endpoint. While there was a dose response for some secondary measures and adverse events, it was not significant.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Brian M. Sandroff, Robert W. Motl, Cristina A. F. Roman, Glenn R. Wylie, John DeLuca, Gary R. Cutter, Ralph H. B. Benedict, Michael G. Dwyer, Robert Zivadinov
Summary: This study provides initial evidence of strong, selective associations among aerobic fitness, cognitive processing speed, and walking endurance in persons with thalamic atrophy as a biomarker for MS-related neurodegeneration. Such data support thalamic atrophy as a moderator of the association among aerobic fitness, cognitive processing speed, and walking endurance in persons with MS. Future research should carefully consider the role of thalamic atrophy when designing trials of aerobic exercise, cognition, and mobility in MS.
JOURNAL OF NEUROLOGY
(2022)
Review
Clinical Neurology
Kyra Theunissen, Guy Plasqui, Annelies Boonen, Bente Brauwers, Annick Timmermans, Pieter Meyns, Kenneth Meijer, Peter Feys
Summary: The review found that pwMS and healthy subjects share similarities in energetically most optimal walking speed, but pwMS have higher Cw. Treadmill walking provides a similar optimum Cw compared to overground walking, but at a higher speed.
NEUROREHABILITATION AND NEURAL REPAIR
(2021)
Article
Clinical Neurology
Lloyd Bradley
Summary: This case report highlights the late-onset side effects of amantadine in a patient with SPMS, which resolved completely upon cessation of the drug. Clinicians managing SPMS symptoms should be aware of the potential cumulative side effects of treatment drugs and their role in precipitating neurological deterioration.
MULTIPLE SCLEROSIS JOURNAL
(2021)
Article
Computer Science, Information Systems
Arash Atrsaei, Farzin Dadashi, Benoit Mariani, Roman Gonzenbach, Kamiar Aminian
Summary: The study developed and validated a new gait speed estimation method based on machine learning, utilizing a sensor on the lower back to predict gait speed in both clinical and home assessments. By validating the algorithm in patients with multiple sclerosis, the robustness of the algorithm in impaired or slow gait was demonstrated. The proposed algorithm showed high performance in detecting walking bouts at home, indicating the feasibility of unsupervised mobility assessment.
IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS
(2021)
Article
Clinical Neurology
Shanshan Chen, Salvador Sierra, Yongyun Shin, Myla D. Goldman
Summary: The study found that MS patients exhibit a concave quadratic gait speed trajectory during the 6MW test, slowing down more than healthy controls, especially at the beginning. 6MW(GST) provides more information than conventional metrics, and can better distinguish between MS patients and healthy individuals.
FRONTIERS IN NEUROLOGY
(2021)
Article
Clinical Neurology
Teresa Costabile, Elisabetta Signoriello, Francesca Lauro, Manuela Altieri, Antonio Rosario Ziello, Alessandro 'Ambrosio, Alvino Bisecco, Giorgia Maniscalco, Simona Bonavita, Antonio Gallo, Vincenzo Brescia Morra, Giacomo Lus, Francesco Sacca, Cinzia Valeria Russo
Summary: This study aims to develop a tablet version of BICAMS (iBICAMS) and evaluate its reliability compared to the paper version. We tested 139 MS patients and found differences between the paper and tablet versions for all three sub-tests of BICAMS. However, the reliability between BICAMS and iBICAMS was high, suggesting that iBICAMS could become a standard in clinical practice.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Rehabilitation
Mariusz Druzbicki, Agnieszka Guzik, Grzegorz Przysada, Lidia Perenc, Agnieszka Brzozowska-Magon, Krzysztof Cygon, Grzegorz Boczula, Halina Bartosik-Psujek
Summary: A study on individuals with multiple sclerosis and severe gait impairment revealed significant improvements in lower-limb muscle strength and walking speed after 15 sessions of exoskeleton-assisted gait training, however, the effects were not long-lasting.
ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
(2021)
Review
Clinical Neurology
Duriel Hardy, Tanuja Chitnis, Emmanuelle Waubant, Brenda Banwell
Summary: Pediatric-onset multiple sclerosis is a relapsing-remitting neuroinflammatory disease characterized by frequent relapses and high lesion burden on MRI. Current treatment focuses on early initiation of disease-modifying therapies to prevent relapses and slow disability progression. Studying the pediatric MS population allows exploration of early-life exposures that contribute to MS development, including perinatal and environmental risk factors.
FRONTIERS IN NEUROLOGY
(2022)
Article
Immunology
Aigli G. Vakrakou, Maria-Evgenia Brinia, Anastasia Alexaki, Evangelos Koumasopoulos, Panos Stathopoulos, Maria-Eleftheria Evangelopoulos, Leonidas Stefanis, Christine Stadelmann-Nessler, Constantinos Kilidireas
Summary: The expanded treatment landscape in relapsing-remitting MS has provided highly effective treatment options, but also increased complexity in managing disease- or drug-related events. Proper decision-making requires thorough understanding of MS immunobiology and underlying mechanisms. The immune system is highly adaptable, but treatments can have harmful effects. Clinicians need to make appropriate clinical decisions for atypical relapses and consider switching therapies for the multiple faces of MS.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Clinical Neurology
Stefanie Hechenberger, Birgit Helmlinger, Stefan Ropele, Lukas Pirpamer, Gerhard Bachmaier, Anna Damulina, Alexander Pichler, Michael Khalil, Christian Enzinger, Daniela Pinter
Summary: This study aimed to assess the prognostic value of cognitive performance in predicting physical impairment and disability progression in patients with multiple sclerosis (MS). The study found that performance in information processing speed was significantly associated with physical impairment and annualized disability progression. The findings suggest that neuropsychological assessment should be integrated into clinical care to support disease management in MS.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Immunology
Seyedmousa Motavallihaghi, Mojgan Ghaemipanaeian, Sara Soleimani Asl, Faeze Foroughi-Parvar, Amir Hossein Maghsood
Summary: This study aimed to investigate the effect of Toxoplasma gondii infection on a multiple sclerosis (MS) mouse model. The results showed that chronic toxoplasmosis could inhibit the development of MS, reduce clinical symptoms, and decrease the levels of inflammatory cells and cytokines. These findings suggest that chronic toxoplasmosis may have therapeutic potential for MS.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Clinical Neurology
Michelle H. Chen, Nancy D. Chiaravalloti, John DeLuca
Summary: Cognitive impairment is a common and disabling symptom in multiple sclerosis, with limited evidence supporting the efficacy of disease-modifying therapies in treating cognitive dysfunction. Cognitive rehabilitation in MS has shown promise in the past decade, with both restorative and compensatory programs proving efficacious. Clinicians should consider this low-cost, low-risk, yet effective treatment approach for their patients.
JOURNAL OF NEUROLOGY
(2021)
Article
Engineering, Biomedical
Carla Winter, Florian Kern, Dominik Gall, Marc Erich Latoschik, Paul Pauli, Ivo Kaethner
Summary: This study evaluated the feasibility and effects of using virtual reality technology in gait rehabilitation for patients, finding that immersive virtual reality training using a head-mounted display can increase motivation and walking speed. The majority of healthy participants and patients preferred training with a head-mounted display.
JOURNAL OF NEUROENGINEERING AND REHABILITATION
(2021)
Article
Clinical Neurology
Walaa A. Kamel, Mohmed Kamel, Almunther Alhasawi, Sameh Elmasry, Fajer AlHamdan, Jasem Y. Al-Hashel
Summary: The study found that taking amantadine is associated with a reduced risk of COVID-19 infection. Old age and a history of contact with COVID cases are risk factors for COVID-19 infection.
FRONTIERS IN NEUROLOGY
(2021)
Review
Clinical Neurology
Samuel F. Hunter, James D. Bowen, Anthony T. Reder
Article
Clinical Neurology
Samuel F. Hunter, Mark Agius, Deborah M. Miller, Gary Cutter, Luigi Barbato, Kevin McCague, Xiangyi Meng, Neetu Agashivala, Peter Chin, Eric Hollander
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2016)
Article
Clinical Neurology
Gavin Giovannoni, Jeffrey A. Cohen, Alasdair J. Coles, Hans-Peter Hartung, Eva Havrdova, Krzysztof W. Selmaj, David H. Margolin, Stephen L. Lake, Susan M. Kaup, Michael A. Panzara, D. Alastair S. Compston
Article
Clinical Neurology
Robert Zivadinov, Jennie Medin, Nasreen Khan, Jonathan R. Korn, Niels Bergsland, Michael G. Dwyer, Tanuja Chitnis, Robert T. Naismith, Enrique Alvarez, Peter Kinkel, Stanley Cohan, Samuel F. Hunter, Diego Silva, Bianca Weinstock-Guttman
JOURNAL OF NEUROIMAGING
(2018)
Article
Clinical Neurology
Jeffrey A. Cohen, Samuel F. Hunter, Theodore R. Brown, Mark Gudesblatt, Ben W. Thrower, Lily Llorens, Cindy J. Souza-Prien, April E. Ruby, David N. Chernoff, Rajiv Patni
MULTIPLE SCLEROSIS JOURNAL
(2019)
Article
Clinical Neurology
Edward Fox, Keith Edwards, Gordon Burch, Daniel R. Wynn, Chris LaGanke, Heidi Crayton, Samuel F. Hunter, Cynthia Huffman, Edward Kim, Linda Pestreich, Kevin McCague, Luigi Barbato
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2014)
Editorial Material
Clinical Neurology
Samuel F. Hunter, Jonathan Calkwood, Daniel Kantor
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2019)
Article
Clinical Neurology
Samuel F. Hunter, Florian P. Thomas, Mark Cascione, Ian M. Williams, Xiangyi Meng, Lesley Schofield, Jamie L. Weiss, Nadia Tenenbaum, Bruce A. C. Cree
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2020)
Review
Pharmacology & Pharmacy
Jerold Chun, Gavin Giovannoni, Samuel F. Hunter
Summary: Lysophospholipids, particularly sphingosine 1-phosphate (S1P), act through G protein-coupled receptors (GPCRs) and have complex effects on physiological and pathophysiological events. S1PR modulators, including fingolimod, siponimod, and ozanimod, have been approved for multiple sclerosis (MS) treatment, with others like ponesimod and etrasimod in clinical development. These modulators show subtype specificity for S1PRs, influencing downstream effects, and can act as both agonists and functional antagonists.
Article
Clinical Neurology
Samuel F. Hunter, Rany A. Aburashed, Raed Alroughani, Andrew Chan, Dominique Dive, Sara Eichau, Daniel Kantor, Ho Jin Kim, Jan Lycke, Richard A. L. Macdonell, Carlo Pozzilli, Thomas Scott, Basil Sharrack, Heinz Wiendl, Luke Chung, Nadia Daizadeh, Darren P. Baker, Patrick Vermersch
Summary: The study demonstrated the association between confirmed disability improvement and worsened disability over 9 years among patients with multiple sclerosis treated with alemtuzumab, highlighting the potential of alemtuzumab to change the course of multiple sclerosis.
NEUROLOGY AND THERAPY
(2021)
Article
Clinical Neurology
Antonio Bertolotto, Rafael Arroyo, Elisabeth G. Celius, Giancarlo Comi, Eva Kubala Havrdova, William David Honeycutt, Samuel F. Hunter, Guillermo Izquierdo, Barbara Kornek, Tamara Miller, Dimos D. Mitsikostas, Barry A. Singer, Tjalf Ziemssen, Luke Chung, Nadia Daizadeh, Salman Afsar, Lobat Hashemi, Peter Senior
NEUROLOGY AND THERAPY
(2020)
Article
Health Care Sciences & Services
Samuel F. Hunter
AMERICAN JOURNAL OF MANAGED CARE
(2016)
Article
Health Care Sciences & Services
Luigi Brunetti, Samuel F. Hunter
AMERICAN JOURNAL OF MANAGED CARE
(2014)
Article
Health Care Sciences & Services
Megan Maroney, Samuel F. Hunter
AMERICAN JOURNAL OF MANAGED CARE
(2014)